CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
31 août 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
01 août 2023 16h15 HE
|
CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
26 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
19 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
15 juin 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Royalty Rates for the Medical Devices Industry: Negotiating Licenses, Valuing Medical Technology and Establishing Patent Infringement Damages
04 mai 2023 07h48 HE
|
Research and Markets
Dublin, May 04, 2023 (GLOBE NEWSWIRE) -- The "Royalty Rates for Medical Devices 2022" report has been added to ResearchAndMarkets.com's offering.Royalty Rates for Medical Devices & Diagnostics...
CytoSorbents Reports First Quarter 2023 Results
02 mai 2023 16h15 HE
|
CytoSorbents
PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
26 avr. 2023 07h00 HE
|
CytoSorbents
MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
19 avr. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
29 mars 2023 08h30 HE
|
CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...